Critical periods for the teratogenicity of immune-suppressant Leflunomide in mice

Congenital Anomalies

Volumn 49, Issue 1, 2009, Pages 20-26

  Fukushima, Ryou ^a   Kanamori, Susumu ^a   Hirashiba, Masahiro ^a   Hishikawa, Atsuko ^a   Muranaka, Ri Ichi ^a   Kaneto, Masako ^a   Kitagawa, Hiroshi ^b  

^a SHIONOGI AND CO LTD   (Japan)

^b KOBE UNIVERSITY   (Japan)

Author keywords

Critical period; Development; Leflunomide; Mouse; Teratogenicity

Indexed keywords

LEFLUNOMIDE;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FEMALE; FETAL WELL BEING; GESTATION PERIOD; MALE; MALFORMATION SYNDROME; MOUSE; NONHUMAN; PRENATAL GROWTH; PRIORITY JOURNAL; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; ABNORMALITIES, MULTIPLE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CRITICAL PERIOD (PSYCHOLOGY); EMBRYO LOSS; EMBRYO, MAMMALIAN; FEMALE; FETAL VIABILITY; GESTATIONAL AGE; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MALE; MICE; MICE, INBRED ICR; PREGNANCY;

MUS;

EID: 60349119455     PISSN: 09143505     EISSN: 17414520     Source Type: Journal    
DOI: 10.1111/j.1741-4520.2008.00217.x     Document Type: Article

References (25)

1. Abbott BD, Best DS, Narotsky MG (2005) Teratogenic effects of retinoic acid are modulated in mice lacking expression of epidermal growth factor and transforming growth factor-alpha. Birth Defects Res A Clin Mol Teratol 73 : 204 217.
2. Aventis Pharmaceuticals (2000) Arava™ Leflunomide Cited 18 Dec 2000.] Company World Wide Web Site, http://www.arava.com/
3. Christoffels VM, Habets PE, Franco D et al. (2000) Chamber formation and morphogenesis in the developing mammalian heart. Dev Biol 223 : 266 278.
4. Davis JP, Cain GA, Pitts WJ, Magolda RL, Copeland RA (1996) The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 35 : 1270 1273.
5. DeSesso JM (2006) Comparative features of vertebrate embryology. In : Hood RD (ed.). Developmental and Reproductive Toxicology, A Practical Approach, 2nd edn. Taylor & Francis, Boca Raton, FL, pp. 147 197.
6. Dimitrova P, Skapenko A, Herrmann ML, Schleyerbach R, Kalden JR, Schulze-Koops H (2002) Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. J Immunol 169 : 3392 3399.
7. Fishman MC, Chien KR (1997) Fashioning the vertebrate heart: Earliest embryonic decisions. Development 124 : 2099 2117.
8. Fukushima R, Kanamori S, Hirashiba M et al. (2007) Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Reprod Toxicol 24 : 310 316.
9. Hoffmann-La Roche Inc 2003) Cellcept® (mycophenolate mofetil capsules) Complete Product Information. Company World Wide Web Site by Roche.
10. Kawai Y, Yoshida A, Nakagawa S, Hama T, Mayumi T (1993) Effect of bredinin on early embryonic development in mice. Biol Pharm Bull 16 : 133 136.
11. Kobayashi Y, Matsumoto K, Hoshino Y, Hayano K (1974) Teratogenic effects of a new immunosuppressive agent, bredinin, in the mouse. Teratology 10 (Suppl 87.
12. Landauer W (1954) On the chemical production of developmental abnormalities and of phenocopies in chicken embryos. J Cell Comp Physiol 43 : 261 305.
13. Le Ray C, Coulomb A, Elefant E, Frydman R, Audibert F (2004) Mycophenolate mofetil in pregnancy after renal transplantation: A case of major fetal malformations. Obstet Gynecol 103 : 1091 1094.
14. Levéen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, Betsholtz C (1994) Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 8 : 1875 1887.
15. Morita H, Ariyuki F, Inomata N et al. (1987) Spontaneous malformations in laboratory animals: Frequency of external, internal and skeletal malformations in rats, rabbits and mice. Congenit Anom 27 : 146 206.
16. Okamoto K, Hoshino K, Yoshida A, Kawai Y, Mayumi T, Hama T (1980) Studies on bredinin (II). Effect of guanine derivatives on cytotoxicity and teratogenicity of bredinin in rats. Congenit Anom 20 : 359 364.
17. Okamoto K, Kobayashi Y, Yoshida K et al. (1978) Teratogenic effects of bredinin, new immunosuppressive agent, in rats. Congenit Anom 18 : 227 233.
18. Padmanabhan R, Ahmed I (1997) Retinoic acid-induced asymmetric craniofacial growth and cleft palate in the TO mouse fetus. Reprod Toxicol 11 : 843 860.
19. Sanofi-aventis KK (2003) Leflunomide Summary Basis for Approval submitted to Japan Ministry of Health, Labor and Welfare (Japanese). Japan Pharmacists Education Center, Tokyo In Japanese
20. Siemasko K, Chong AS, Jäck HM, Gong H, Williams JW, Finnegan A (1998) Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production. J Immunol 160 : 1581 1588.
21. Song W, Jackson K, McGuire PG (2000) Degradation of type IV collagen by matrix metalloproteinases is an important step in the epithelial-mesenchymal transformation of the endocardial cushions. Dev Biol 227 : 606 617.
22. Tam PP, Tan SS (1992) The somitogenetic potential of cells in the primitive streak and the tail bud of the organogenesis-stage mouse embryo. Development 115 : 703 715.
23. Xu X, Bringas P Jr., Soriano P, Chai Y (2005) PDGFR-alpha signaling is critical for tooth cusp and palate morphogenesis. Dev Dyn 232 : 75 84.
24. Xu X, Shen J, Mall JW et al. (1999) In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: Mechanisms of action. Biochem Pharmacol 58 : 1405 1413.
25. Xu X, Williams JW, Bremer EG, Finnegan A, Chong AS (1995) Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem 270 : 12398 12403.